Tatva Chintan Pharma Chem (TATVA.BO) Earnings Analysis
Tatva Chintan Pharma Chem (TATVA.BO) next reports earnings on 2026-10-30. Last quarter (2026-07-17) it beat with EPS 7 INR vs 6.05 INR est (+15.7%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E 77.24.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TATVA.BO next report earnings?
| Next earnings date | 2026-10-30 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
TATVA.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-07-17 | 7 INR | 6.05 INR | +15.7% | Beat |
| 2026-05-16 | 4.55 INR | 6.4 INR | -28.9% | Miss |
| 2026-01-21 | 6.8 INR | 4.5 INR | +51.1% | Beat |
| 2025-07-24 | 2.84 INR | 2 INR | +42% | Beat |
| 2025-05-02 | 0.44 INR | 2.2 INR | -80% | Miss |
| 2025-01-28 | 0.1 INR | -0.2 INR | +150% | Beat |
| 2024-10-25 | -0.29 INR | 1.3 INR | -122.3% | Miss |
| 2024-07-24 | 2.23 INR | 5.6 INR | -60.2% | Miss |
Beat rate: 4/8 (50%) over reported quarters with consensus data.
TATVA.BO valuation and analyst view
| Trailing P/E | 77.24 |
|---|---|
| Trailing EPS | 21.961 INR |
| Price / book | 5.08 |
| Dividend yield | 0.06% |
| Market cap | 38.95B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Tatva Chintan Pharma Chem (TATVA.BO)'s next earnings date?
Tatva Chintan Pharma Chem is next scheduled to report on 2026-10-30.
Did TATVA.BO beat earnings last quarter?
In its 2026-07-17 report, TATVA.BO posted EPS of 7 INR versus a 6.05 INR estimate — a beat of 15.7%.
What is TATVA.BO's earnings track record?
Over the last 8 reported quarters with consensus data, TATVA.BO beat estimates 4 times (50%).
What is TATVA.BO's current P/E ratio and EPS?
TATVA.BO trades at a trailing P/E of 77.24 on trailing EPS of 21.96062328269691 INR.
What do analysts rate TATVA.BO?
TATVA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.